Investment banks Cowan and BMO Capital Markets are advising the initial public offering (IPO), with legal counsel from Lowenstein Sandler and Goodwin Procter.
Regado Biosciences, a US-based thrombosis treatment company backed by local drugs group Baxter’s corporate venturing unit, plans to raise $75m in its flotation on the Nasdaq stock exchange.
Investment banks Cowan and BMO Capital Markets are advising the initial public offering (IPO), with legal counsel from Lowenstein Sandler and Goodwin Procter.
Shareholders in the pre-revenue company include venture capital firms Domain Associates (19.2%), Quaker BioVentures (12.7%), Edmond de Rothschild Investment Partners (12.4%), RMI Investments (14.2%) and Aurora Funds (7.9%).
Regardo…
